Jafron Biomedical Co.,Ltd. (SHE:300529)
China · Delayed Price · Currency is CNY 19.79
-0.25 (-1.25%)
At close: Feb 13, 2026
Jafron Biomedical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | 481.79 | 820.2 | 436.49 | 889.56 | 1,197 | 875.24 |
Depreciation & Amortization | 124.97 | 124.97 | 94.79 | 73.99 | 54.06 | 36.73 |
Other Amortization | 19.18 | 19.18 | 18.19 | 8.63 | 4.68 | 2.17 |
Loss (Gain) From Sale of Assets | -3.64 | -3.64 | -6.72 | -0.86 | -0.98 | - |
Asset Writedown & Restructuring Costs | 6.24 | 6.24 | 27.07 | 7.86 | 1.15 | 0.48 |
Loss (Gain) From Sale of Investments | -43.11 | -43.11 | - | -10.51 | -28.72 | -15.19 |
Provision & Write-off of Bad Debts | - | - | - | -1.99 | 6.76 | 0.82 |
Other Operating Activities | 103.39 | 63.35 | 45 | 27.72 | 7.69 | -1.1 |
Change in Accounts Receivable | -8.22 | -8.22 | 277.22 | -7.9 | -110.41 | -83.41 |
Change in Inventory | 41.56 | 41.56 | -37.3 | -152.74 | -75.93 | -28.29 |
Change in Accounts Payable | 0.45 | 0.45 | 52.14 | 60.66 | 203.27 | 150.6 |
Change in Other Net Operating Assets | 35.49 | 35.49 | 10.87 | -8.59 | 8.27 | 22.35 |
Operating Cash Flow | 752.62 | 1,051 | 916.74 | 883.8 | 1,249 | 957.49 |
Operating Cash Flow Growth | -37.19% | 14.64% | 3.73% | -29.26% | 30.49% | 64.09% |
Capital Expenditures | -173.94 | -235.14 | -247.25 | -475.89 | -537.41 | -357.11 |
Sale of Property, Plant & Equipment | 2.89 | 5.34 | 12.6 | 6.91 | 0.99 | 0.81 |
Cash Acquisitions | - | - | - | -0.18 | - | - |
Investment in Securities | -16.17 | -908.45 | -15 | 163.26 | -133.8 | - |
Other Investing Activities | -4.93 | 10.78 | - | - | - | 15.19 |
Investing Cash Flow | -192.14 | -1,127 | -249.65 | -305.9 | -670.22 | -341.11 |
Short-Term Debt Issued | - | 1 | - | - | - | - |
Long-Term Debt Issued | - | 325.08 | 762.92 | 296.32 | 998.3 | - |
Total Debt Issued | 109.92 | 326.08 | 762.92 | 296.32 | 998.3 | - |
Long-Term Debt Repaid | - | -654.5 | -349.47 | -6.11 | -6.02 | - |
Net Debt Issued (Repaid) | -212.55 | -328.43 | 413.45 | 290.21 | 992.28 | - |
Issuance of Common Stock | 14.22 | 14.22 | 123.81 | 67.29 | 195.09 | 72.07 |
Repurchase of Common Stock | -371.28 | -371.28 | -382.58 | -5.19 | -500.13 | -8.29 |
Common Dividends Paid | -646.12 | -340.12 | -561.79 | -729.42 | -531.02 | -377.81 |
Other Financing Activities | 357.13 | 35.78 | -44.8 | 11.19 | 8.94 | 1 |
Financing Cash Flow | -858.6 | -989.82 | -451.91 | -365.93 | 165.18 | -313.03 |
Foreign Exchange Rate Adjustments | 0.69 | 0.43 | 0.01 | -0.04 | -0 | -0.04 |
Net Cash Flow | -297.43 | -1,066 | 215.19 | 211.93 | 744.37 | 303.32 |
Free Cash Flow | 578.69 | 815.85 | 669.49 | 407.91 | 712 | 600.37 |
Free Cash Flow Growth | -33.68% | 21.86% | 64.13% | -42.71% | 18.59% | 65.47% |
Free Cash Flow Margin | 28.40% | 30.47% | 34.83% | 16.37% | 26.61% | 30.78% |
Free Cash Flow Per Share | 0.76 | 1.04 | 0.84 | 0.51 | 0.89 | 0.74 |
Cash Income Tax Paid | 424.66 | 468.12 | 255.53 | 441.93 | 427.62 | 297.68 |
Levered Free Cash Flow | 381.85 | 510.67 | 535.7 | 18.61 | 228.28 | 252.21 |
Unlevered Free Cash Flow | 416.85 | 550.49 | 569.66 | 41.13 | 233.85 | 252.21 |
Change in Working Capital | 63.81 | 63.81 | 301.92 | -110.6 | 7.96 | 58.35 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.